Genomics in Cancer Care Market Size & Growth Forecast 2027–2036, By Segments (Product, Application, Technology), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Genomics in Cancer Care Market size was worth USD 27.01 billion in 2026 and is expected to grow at a 15.2% CAGR between 2027 and 2036, surpassing USD 111.19 billion by 2036. The industry revenue for 2027 is calculated at USD 30.47 billion.
Get more details on this report
Request Free Sample ReportGenomics in Cancer Care Market Intelligence Snapshot
Regional Market Dynamics
- North America captured a 38.90% market share in 2026, supported by widespread genomic testing, established oncology infrastructure, and routine use of precision medicine across healthcare providers.
- Asia Pacific is projected to grow at a 17.81% CAGR as molecular testing expands, cancer diagnosis capabilities improve, and genomic tools become more integrated into oncology care pathways.
Segment Momentum
- Consumables captured 57.54% of the market in 2026 because every genomic test requires recurring use of kits, reagents, assays, and sample preparation materials, ensuring stable demand.
- Drug Discovery & Development is expanding rapidly as organizations increasingly use genomic insights to identify therapeutic targets, improve candidate selection, and strengthen oncology development workflows.
Market Expansion Drivers
- Rising cancer burden driving demand for precision oncology and personalized genomic diagnostics.
- Advancements in next-generation sequencing reducing costs and accelerating genomic testing adoption.
- Government-funded genome mapping initiatives expanding clinical research and population genomics programs.
Leading Market Participants
- Leading companies in the genomics in cancer care market include Illumina, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (United States), Abbott Laboratories (United States), Bio-Rad Laboratories, Inc. (United States), Pacific Biosciences of California, Inc. (United States), Beckman Coulter, Inc. (United States), Quest Diagnostics Incorporated (United States), Revvity, Inc. (United States), Thermo Fisher Scientific Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 27.01 billion
- 2027 Estimated Market Size: USD 30.47 billion.
- Projected Market Size: USD 111.19 billion by 2036
- Growth Forecast: 15.2% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Consumables (Product) | Diagnostics (Application) | Genome Sequencing (Technology)
- Emerging Opportunity Segment: Services (Product) | Drug Discovery & Development (Application) | Genome Sequencing (Technology)
Market Growth Drivers and Industry Trends
Rising cancer burden driving demand for precision oncology and personalized genomic diagnostics
The growing prevalence of cancer is strengthening the genomics in cancer care market as healthcare systems increasingly seek diagnostic approaches that can distinguish tumors according to their molecular and genetic characteristics. Genomic profiling enables clinicians to identify disease-associated alterations, support more precise cancer classification, and guide treatment selection for patients with specific biological profiles. As oncology care moves toward individualized treatment pathways, genomic diagnostics are becoming increasingly relevant for identifying actionable biomarkers, assessing potential treatment responses, and supporting therapeutic decisions across diverse cancer types.
Advancements in next-generation sequencing reducing costs and accelerating genomic testing adoption
Technological improvements in next-generation sequencing are making genomic analysis more accessible, supporting broader adoption across oncology settings and reinforcing the genomics in cancer care market. Enhanced sequencing capabilities can process complex genetic information more efficiently while improvements in testing workflows and analytical technologies help simplify the interpretation of genomic data. Greater accessibility of sequencing-based testing allows healthcare providers to incorporate molecular profiling into diagnostic and treatment pathways, while improved testing economics can encourage wider use across hospitals, specialized cancer centers, and clinical laboratories.
Government-funded genome mapping initiatives expanding clinical research and population genomics programs
Government support for genome mapping and related genomic research is expanding the infrastructure needed to study genetic variation, disease susceptibility, and cancer biology, creating additional opportunities for the genomics in cancer care market. Publicly funded initiatives can provide researchers with broader genomic datasets, sequencing capabilities, and collaborative research platforms that support the identification of cancer-associated genetic characteristics. These programs also facilitate population-level studies and clinical research, helping improve understanding of disease patterns and strengthening the evidence base for incorporating genomic information into cancer diagnosis and treatment.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising cancer burden driving demand for precision oncology and personalized genomic diagnostics | 2.40% | High | North America, Europe | High | Near Term |
| Advancements in next-generation sequencing reducing costs and accelerating genomic testing adoption | 2.20% | High | North America, Asia Pacific | High | Mid Term |
| Government-funded genome mapping initiatives expanding clinical research and population genomics programs | 1.90% | High | Asia Pacific, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for 38.90% of the genomics in cancer care market in 2026, supported by advanced oncology infrastructure, established genomic testing capabilities, and strong integration of precision medicine into cancer diagnosis and treatment. Greater adoption of molecular profiling and sequencing technologies is enabling clinicians to identify actionable genetic alterations and support more individualized treatment decisions. Robust research activity, specialized cancer centers, and increasing emphasis on early detection and targeted therapies further strengthen demand for genomic applications across oncology care pathways.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing regional market as healthcare systems expand their capacity for advanced diagnostics and precision oncology. Increasing cancer burden, improving access to genomic testing, and growing investment in specialized healthcare infrastructure are broadening the use of molecular diagnostics and sequencing technologies. Greater awareness among clinicians and patients, combined with initiatives aimed at strengthening cancer screening and personalized treatment, is creating favorable conditions for wider adoption of genomics-based cancer care.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Molecular Diagnostics IntegrationGermany is strengthening genomics in cancer care through broader adoption of molecular diagnostics within routine oncology practice. Clinical laboratories and healthcare providers in Germany are improving access to genomic testing that supports personalized treatment strategies.
France 🇫🇷
Personalized Oncology NetworksFrance is expanding collaborative precision oncology programs that connect genomic testing with multidisciplinary cancer care. Healthcare institutions in France emphasize standardized interpretation of genomic data to support targeted therapeutic decisions.
Italy 🇮🇹
Translational Genomics FocusItaly is advancing genomics in cancer care by linking research findings with routine clinical oncology practice. Healthcare providers in Italy are increasing the use of genomic profiling to identify actionable mutations and optimize personalized treatment pathways.
Japan 🇯🇵
Clinical Genomics AdoptionJapan is integrating genomic testing into oncology care with emphasis on precision treatment selection and standardized clinical workflows. Healthcare providers in Japan continue expanding access to validated genomic assays for patients with complex cancers.
South Korea 🇰🇷
Sequencing Infrastructure GrowthSouth Korea is investing in next-generation sequencing capabilities that strengthen genomics in cancer care across hospitals and diagnostic centers. Clinical teams in South Korea are incorporating genomic insights to improve treatment planning and patient stratification.
United States 🇺🇸
Precision Oncology LeadershipThe U.S. genomics in cancer care market continues expanding comprehensive genomic profiling to guide targeted therapies and clinical decision-making. Healthcare organizations in the U.S. are integrating sequencing technologies with precision oncology programs across multiple cancer types.
Segment Leadership and Growth Trends
Genomics in Cancer Care Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Consumables (Largest Segment) vs Services (Fastest-Growing Segment)
In the genomics in cancer care market, consumables represented the largest product segment in 2026, accounting for 57.54% share, owing to their recurring use across genomic testing, sequencing, sample preparation, and molecular analysis workflows. The expansion of genomic-based cancer testing requires a continuous supply of reagents, kits, and other laboratory materials, making consumables an essential component of routine testing operations. Increasing use of molecular profiling and precision oncology further supports recurring demand as healthcare and research facilities integrate genomic information into cancer diagnosis and treatment decisions.
Services are emerging as the fastest-growing product category as cancer care increasingly depends on specialized genomic analysis, interpretation, and technical support. Healthcare providers and research organizations often require expertise to manage complex genomic datasets and translate molecular findings into clinically useful insights. Greater adoption of precision medicine is therefore encouraging demand for specialized genomic services that complement laboratory technologies and help streamline the use of genomic information in cancer care.
Application Segment Analysis: Diagnostics (Largest Segment) vs Drug Discovery & Development (Fastest-Growing Segment)
Diagnostics held the largest share of the genomics in cancer care market in 2026, reflecting the growing role of genomic information in identifying cancer characteristics and supporting more precise clinical decision-making. Genomic diagnostics can help identify molecular alterations, classify disease profiles, and guide the selection of appropriate therapeutic strategies. Increasing emphasis on early detection, molecular characterization, and personalized treatment is strengthening the integration of genomic diagnostics into cancer management.
Drug discovery & development is gaining momentum as pharmaceutical research increasingly uses genomic information to identify disease mechanisms, discover therapeutic targets, and support more precise development strategies. Genomic datasets can help researchers understand molecular drivers of cancer and identify patient populations that may respond to specific therapies. The growing shift toward targeted and biomarker-informed drug development is consequently expanding the application of genomics beyond diagnosis and into therapeutic innovation.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Instruments, Consumables, Services | Consumables | Services |
| Application | Diagnostics, Personalized Medicine, Drug Discovery & Development, Research | Diagnostics | Drug Discovery & Development |
| Technology | Genome Sequencing, PCR, Microarrays, Nuclei Acid Extraction and Purification, Other | Genome Sequencing | Genome Sequencing |
Competitive Landscape and Market Positioning
Major players in the genomics in cancer care market:
1. Illumina Inc. (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Agilent Technologies Inc. (United States)
4. Abbott Laboratories (United States)
5. Bio-Rad Laboratories Inc. (United States)
6. Pacific Biosciences of California Inc. (United States)
7. Beckman Coulter Inc. (United States)
8. Quest Diagnostics Incorporated (United States)
9. Revvity Inc. (United States)
10. Thermo Fisher Scientific Inc. (United States)
Expanding application of genomic profiling is transforming the genomics in cancer care market, enabling more precise and personalized treatment pathways. Integration of AI-based analysis tools is improving diagnostic accuracy and clinical decision-making. Continuous innovation is strengthening oncology research capabilities within the genomics in cancer care market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Illumina Inc. (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Agilent Technologies Inc. (United States) | |||||||
| Abbott Laboratories (United States) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Pacific Biosciences of California Inc. (United States) | |||||||
| Beckman Coulter Inc. (United States) | |||||||
| Quest Diagnostics Incorporated (United States) | |||||||
| Revvity Inc. (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Guardant Health | May-25 | Guardant Health introduced Guardant360 Tissue in May 2025, a multi-omic tissue profiling solution designed to deliver results in under two weeks while reducing tissue material requirements by approximately 40% compared to conventional workflows. The development strengthens its precision oncology portfolio by improving efficiency and scalability of genomic tumor profiling in clinical cancer care. |
| Exact Sciences | Apr-25 | Exact Sciences launched the OncoDetect MRD assay in April 2025, enabling detection of up to 200 circulating tumor DNA variants and identifying potential cancer recurrence up to two years earlier than imaging-based methods. The solution enhances minimal residual disease monitoring capabilities and supports earlier clinical intervention in oncology care pathways. |
| Guardant Health and ConcertAI | Jan-25 | Guardant Health and ConcertAI launched a data-as-a-service platform in January 2025 integrating approximately 5.5 million clinical records with tumor profiling data across more than 60 cancer types. The initiative enhances large-scale oncology data analytics capabilities, enabling improved clinical insights, research acceleration, and AI-driven precision medicine applications. |
| PacBio | Nov-24 | PacBio introduced the Vega benchtop sequencing system in November 2024, extending HiFi sequencing capabilities to smaller laboratories. The system expands access to high-accuracy long-read sequencing, supporting decentralized genomic research workflows and increasing adoption of advanced sequencing technologies in clinical and translational cancer research settings. |
| Eurofins Genomics AgriGenomics Europe and Gencove | Apr-24 | Eurofins Genomics AgriGenomics Europe and Gencove entered a collaboration in April 2024 to deliver a comprehensive imputed whole-genome sequencing (ipWGS) solution across Europe. The partnership focuses on enabling high-throughput and cost-efficient genomic sequencing workflows, strengthening accessibility of large-scale genome analysis for research and precision oncology applications in the European genomics ecosystem. |
| GE Healthcare and SOPHiA GENETICS | Nov-21 | GE Healthcare collaborated with SOPHiA GENETICS in November 2021 to advance precision medicine capabilities and improve accessibility of genomic-driven cancer care. The partnership integrates analytics and healthcare technologies to support broader adoption of advanced diagnostic tools, aiming to enhance clinical decision-making and expand precision oncology applications globally. |
| SCHOTT AG | Sep-21 | SCHOTT AG acquired Applied Microarrays Inc. in September 2021 to strengthen its diagnostics business and expand its manufacturing footprint in the United States. The acquisition enhances SCHOTT’s capabilities in microarray-based technologies, supporting broader diagnostic development and reinforcing its position within the cancer genomics and life sciences tooling ecosystem. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Genomics in Cancer Care Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Cancer Type | Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Cancers |
| Workflow Stage | Sample Preparation & Extraction, Sequencing & Data Generation, Bioinformatics & Interpretation, Clinical Reporting & Decision Support |
| Sample Type | Tissue Samples, Blood & Liquid Biopsy Samples, Bone Marrow Samples, Other Clinical Samples |
Genomics in Cancer Care Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Precision Oncology Adoption Assessment |
|
| Genomic Testing Workflow Optimization |
|
| Companion Diagnostics Integration Strategy |
|
Need a different cut of the data?
Request Custom ResearchHow large is the genomics in cancer care market?
How is the genomics in cancer care industry projected to perform over the next decade?
How is rising cancer burden accelerating integration of genomic diagnostics into routine oncology decision-making?
What role is next-generation sequencing advancement playing in expanding clinical adoption of cancer genomics testing?
Why do Consumables hold the largest share of the genomics in cancer care market?
Why is Drug Discovery & Development the fastest-growing application in the genomics in cancer care market?
Why is North America the largest genomics in cancer care market?
What is fueling rapid growth in the genomics in cancer care market across Asia Pacific?
Who holds a significant market share in the genomics in cancer care landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization